
IMFINZI Receives Priority Review in US for Muscle-Invasive Bladder Cancer
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) and granted it Priority Review. The application seeks approval…













